RxDoctor Payments Data

Matthew Thompson, MD

Ophthalmology · Green Bay, WINPI 1659336733

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Rxsight Inc accounts for 64.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $1,672, 10.0 times the $168 reported in 2019.

$2,675in general payments, 2019–2025

Across 37 payments — averaging $72.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$2K
  • Alcon$622
  • AbbVie$129
  • The Cameron-ehlen Group, Inc.$81
  • Glaukos Corporation$37
  • Novartis$20
  • plus $70 from 5 others

What the payments were for

  • Consulting fees$1,50056%
  • Speaking & faculty fees$321%
  • Food & beverage$1,14343%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,675 in reported general payments places this provider in the 80th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$241,503
Medicare patients
389
Services billed
1,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine55$53,061
Prednisolone Acetate511$23,121
Fluorometholone249$19,399
Loteprednol Etabonate77$18,757
MoxifloxacinMoxifloxacin Hcl507$15,096
LotemaxLoteprednol Etabonate23$10,641
Cyclosporine19$9,201
Difluprednate44$8,842
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$6,714
CombiganBrimonidine Tartrate/Timolol12$3,722
Ketorolac Tromethamine102$3,645
Latanoprost326$2,945
ValacyclovirValacyclovir Hcl21$2,838
Tobramycin-DexamethasoneTobramycin/Dexamethasone55$2,674
Timolol Maleate162$1,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$129$56,78367 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →